SAN FRANCISCO, Dec. 20 - MitoKor said Thursday it had raised $25 million in private equity funding.
Investors included the San Diego, Calif.-based company's largest shareholders, Alta Partners, Forward Ventures, Domain Associates/3i Bioscience Investment Trust, MDS Capital Corp., and S.R. One, in addition to new investors Federated Kaufmann Fund, Orbitex Health and Biotechnology Funds, Palladin Group, China Development Industrial Bank, First Bio Venture Capital, Emerging Growth Management Funds, and DRW Venture Partners.
In 1997, MitoKor raised $16.1 million in venture capital.
MitoKor is hoping to use its knowledge of mitochondria to develop therapeutic treatments for diseases stemming from aging. The company has completed sequencing the mitochondrial genomes of more than 600 people.